Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) has announced it will host a conference call and webcast on November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results. Interested parties can pre-register for the call, and a live audio webcast with accompanying slides will be accessible through the company's website. A replay of the webcast will be available for 90 days following the event.

Apellis is a global biopharmaceutical company focused on developing life-changing therapies for challenging diseases. They have introduced the first new class of complement medicine in 15 years and currently have two approved medicines targeting C3, including the first-ever therapy for geographic atrophy, a leading cause of blindness worldwide. The company aims to further explore the potential of targeting C3 across various retinal, rare, and neurological diseases.

Positive

• Apellis has two approved medicines targeting C3
• Developed first-ever therapy for geographic atrophy, a leading cause of blindness

Negative

• None.

News Market Reaction

+2.68%

1 alert

+2.68% News Effect

On the day this news was published, APLS gained 2.68%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2024 financial results on Tuesday, November 5, 2024, at 8:30 a.m. ET.

To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.

About Apellis 
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178

FAQ

When will Apellis Pharmaceuticals (APLS) report its Q3 2024 financial results?

Apellis Pharmaceuticals (APLS) will report its third quarter 2024 financial results on Tuesday, November 5, 2024, during a conference call and webcast scheduled for 8:30 a.m. ET.

How can investors access Apellis Pharmaceuticals' (APLS) Q3 2024 earnings call?

Investors can access Apellis Pharmaceuticals' (APLS) Q3 2024 earnings call by pre-registering for the call through the provided link. Additionally, a live audio webcast and accompanying slides will be available on the company's website under the 'Events and Presentations' page in the 'Investors and Media' section.

What are the key therapeutic areas Apellis Pharmaceuticals (APLS) is focusing on?

Apellis Pharmaceuticals (APLS) is focusing on developing therapies for serious retinal, rare, and neurological diseases by targeting C3. They have already developed the first-ever therapy for geographic atrophy, a leading cause of blindness worldwide.

How long will the replay of Apellis Pharmaceuticals' (APLS) Q3 2024 earnings webcast be available?

The replay of Apellis Pharmaceuticals' (APLS) Q3 2024 earnings webcast will be available for 90 days following the event on November 5, 2024.